Abstract
Background: Although it is known that Alzheimer's disease (AD) is associated with the progressive accumulation of amyloid β-peptide (Aβ) in the human brain, its pathogenic role has to be completely clarified. Aβ moves from the bloodbrain barrier to the plasma and an increased Aβ production in brain could be associated with higher Aβ concentrations in blood. A recent study has evaluated Aβ40 and Aβ42 levels in human red blood cells (RBCs) with evidence of agedependent higher Aβ concentration in RBCs.
Objective: The aim of the study was to investigate if erythrocyte associated Aβ (iAβ) levels could be different in subjects affected by dementia in comparison with controls and according to the patient’s cognitive impairment or different dementia subtypes.
Method: To answer these questions we assessed iAβ40 and iAβ42 levels in 116 patients: 32 healthy controls, 39 with diagnosis of vascular dementia (VaD), 14 mild cognitive impairment (MCI) and 31 AD.
Results: In this population we found significant differences in iAβ42 between controls and cognitive impaired patients. Moreover, iAβ42 significantly differed between dementia vs MCI. AD also showed different iAβ42 levels as compared to VaD. Conversely, no differences were found for iAβ40. All the analyses were adjusted for potential confounders like age, gender and Hb concentration. A direct correlation between increasing iAβ42 concentration and the progression of the cognitive decline using the MMSE score as continuous variable was also found.
Conclusion: Our findings support the evidence that iAβ42 could be an instrument to early recognize dementia and predict cognitive impairment.
Keywords: Alzheimer's disease, cognitive impairment, amyloid β peptide, biomarker, erythrocyte associated Aβ42, Aβ40.
Current Alzheimer Research
Title:Erythrocyte Associated Amyloid-β as Potential Biomarker to Diagnose Dementia
Volume: 15 Issue: 4
Author(s): Michele Lauriola, Giulia Paroni*, Filomena Ciccone, Grazia D`Onofrio, Leandro Cascavilla, Francesco Paris, Carolina Gravina, Maria Urbano, Davide Seripa and Antonio Greco
Affiliation:
- Complex Unit of Geriatrics, Department of Medical Sciences, I.R.C.C.S. "Casa Sollievo della Sofferenza", 71013 San Giovanni Rotondo (FG),Italy
Keywords: Alzheimer's disease, cognitive impairment, amyloid β peptide, biomarker, erythrocyte associated Aβ42, Aβ40.
Abstract: Background: Although it is known that Alzheimer's disease (AD) is associated with the progressive accumulation of amyloid β-peptide (Aβ) in the human brain, its pathogenic role has to be completely clarified. Aβ moves from the bloodbrain barrier to the plasma and an increased Aβ production in brain could be associated with higher Aβ concentrations in blood. A recent study has evaluated Aβ40 and Aβ42 levels in human red blood cells (RBCs) with evidence of agedependent higher Aβ concentration in RBCs.
Objective: The aim of the study was to investigate if erythrocyte associated Aβ (iAβ) levels could be different in subjects affected by dementia in comparison with controls and according to the patient’s cognitive impairment or different dementia subtypes.
Method: To answer these questions we assessed iAβ40 and iAβ42 levels in 116 patients: 32 healthy controls, 39 with diagnosis of vascular dementia (VaD), 14 mild cognitive impairment (MCI) and 31 AD.
Results: In this population we found significant differences in iAβ42 between controls and cognitive impaired patients. Moreover, iAβ42 significantly differed between dementia vs MCI. AD also showed different iAβ42 levels as compared to VaD. Conversely, no differences were found for iAβ40. All the analyses were adjusted for potential confounders like age, gender and Hb concentration. A direct correlation between increasing iAβ42 concentration and the progression of the cognitive decline using the MMSE score as continuous variable was also found.
Conclusion: Our findings support the evidence that iAβ42 could be an instrument to early recognize dementia and predict cognitive impairment.
Export Options
About this article
Cite this article as:
Lauriola Michele , Paroni Giulia *, Ciccone Filomena , D`Onofrio Grazia, Cascavilla Leandro , Paris Francesco , Gravina Carolina , Urbano Maria , Seripa Davide and Greco Antonio , Erythrocyte Associated Amyloid-β as Potential Biomarker to Diagnose Dementia, Current Alzheimer Research 2018; 15 (4) . https://dx.doi.org/10.2174/1567205014666171110160556
DOI https://dx.doi.org/10.2174/1567205014666171110160556 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer’s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Was Phenserine a Failure or Were Investigators Mislead by Methods?
Current Alzheimer Research Neuropharmacology of the Endocannabinoid Signaling System-Molecular Mechanisms, Biological Actions and Synaptic Plasticity
Current Neuropharmacology The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer’s Disease
Current Alzheimer Research Defining Dystonic Tremor
Current Neuropharmacology Co-ultraPEALut: Role in Preclinical and Clinical Delirium Manifestations
CNS & Neurological Disorders - Drug Targets Agents Complexing Copper as a Therapeutic Strategy for the Treatment of Alzheimers Disease
Current Alzheimer Research Interplay between the APOE Genotype and Possible Plasma Biomarkers in Alzheimer’s Disease
Current Alzheimer Research Neurorestorative Effect of Urinary Bladder Matrix-Mediated Neural Stem Cell Transplantation Following Traumatic Brain Injury in Rats
CNS & Neurological Disorders - Drug Targets Current Advances on Different Kinases Involved in Tau Phosphorylation, and Implications in Alzheimers Disease and Tauopathies
Current Alzheimer Research Molecular Interaction of Human Brain Acetylcholinesterase with a Natural Inhibitor Huperzine-B: An Enzoinformatics Approach
CNS & Neurological Disorders - Drug Targets Pharmacological Management of Type 2 Diabetes Mellitus: An Update
Current Diabetes Reviews Choice of Antihypertensive Treatment in Subjects with Pre-Diabetes. Is There a Dream After the Navigator
Current Vascular Pharmacology Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration
Current Vascular Pharmacology Simple Choline Esters as Potential Anti-Alzheimer Agents
Current Pharmaceutical Design Epidemiology and Etiology of Alzheimer’s disease: From Genetic to Non- Genetic Factors
Current Alzheimer Research Ion Channel Defects in Idiopathic Epilepsies
Current Pharmaceutical Design Easy Screening for Mild Alzheimer's Disease and Mild Cognitive Impairment from Elderly Speech
Current Alzheimer Research Molecular Interaction of Acetylcholinesterase with Carnosic Acid Derivatives: A Neuroinformatics Study
CNS & Neurological Disorders - Drug Targets Alzheimers Disease Burdens African-Americans: A Review of Epidemiological Risk Factors and Implications for Prevention and Treatment
Current Psychiatry Reviews New Trends in the Design of Drugs Against Alzheimers Disease
Current Medicinal Chemistry